<DOC>
	<DOCNO>NCT02929706</DOCNO>
	<brief_summary>NUDT15 R139C comfirmed associate thiopurine-induced leukopenia inflammatory bowel disease ( IBD ) cohort.The present study aim explor follow question : optimize thiopurine dose NUDT15 genotype reduce thiopurine-induced leucopenia ? What influence optimize strategy clinical outcome ? Thus , conduct randomise control study.Subject conventional group detect NUDT15 genotype thiopurine use optimise dosage accord genotype.While subject control group follow conventional monitor strategy.The primary endpoint rate leukopenia.The secondary endopoint efficacy thiopurine.The follow duration 1 year .</brief_summary>
	<brief_title>Effectiveness Thiopurine Dose Optimization NUDT 15 R139C Reducing Thiopurine-induced Leucopenia Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Leukopenia</mesh_term>
	<criteria>diagnosis IBD indication use thiopurine Contraindication thiopurine Previous use thiopurine cotreatment 5ASA allopurinol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>